Vogenx plans to offer 6.25 million shares for$11 to $13 apiece in its initial public offering.
The biopharmaceutical company, which develops metabolic and gastrointestinal treatments, shared the size and pricing of its IPO Monday after initially filing in July.
It plans to trade on Nasdaq under the ticker VOGX.
Vogenx plans to use proceeds from the offering for the development of mizagliflozin, a pill being developed for post-bariatric hypoglycemia.
The proceeds will also go toward other research and development, as well as pay accrued expenses including salaries and bonuses.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.